Transcode Therapeutics (RNAZ) Current Deferred Revenue (2021 - 2026)

Transcode Therapeutics' (RNAZ) quarterly Current Deferred Revenue came in at $85262.0 in Q1 2026, up 235.57% on a QoQ basis from $25408.0 in Q4 2024.

Transcode Therapeutics (RNAZ) Current Deferred Revenue (2021 - 2026) Analysis & Trends

Transcode Therapeutics (RNAZ) has 5 years of Current Deferred Revenue data on file, last reported at $85262.0 in Q1 2026.

Quarterly Current Deferred Revenue changed N/A year-over-year to $85262.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85262.0 (changed N/A YoY) and the FY2024 annual result came in at $25408.0, down 6.09% from the prior year.
Current Deferred Revenue rose to $85262.0 in Q1 2026, from $25408.0 in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $85262.0 in Q1 2026 to a low of $23538.0 in Q1 2022.
A 4-year average of $41089.1 and a median of $25408.0 in 2024 frame the typical range for Current Deferred Revenue.
Annual changes were most pronounced in 2022 — Current Deferred Revenue tumbled 90.65% — and 2023, when it soared 247.3%.
Tracing RNAZ's Current Deferred Revenue over 4 years: stood at $23538.0 in 2022, then increased by 14.95% to $27057.0 in 2023, then slipped by 6.09% to $25408.0 in 2024, then soared by 235.57% to $85262.0 in 2026.
The last three Current Deferred Revenue figures came in at $85262.0 (Q1 2026), $25408.0 (Q4 2024), and $25408.0 (Q1 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Transcode Therapeutics	2.84 Mn	2.84 Mn	-

Download Data